Generation and validation of antibody 42B1 recognizing galactose-deficient IgG for diagnosis of chronic inflammatory diseases

Morishima, Naoki; Iwaisako, Maki; Kamada, Yoshihiro; Nakano, Miyako; Shiida, Masafumi; Ono, Tatsuya; Sonoda, Reika; Uemura, Risa; Sakon, Daisuke; Shimosaka, Munefumi; Takamatsu, Shinji; Kondo, Jumpei; Yoshihara, Takeo; Shinzaki, Shinichiro; Mita, Eiji; Takehara, Tetsuo; Kumada, Takashi; Yamada, Makoto; Miyoshi, Eiji

doi:https://doi.org/10.1016/j.cca.2024.120052

Generation and validation of antibody 42B1 recognizing galactose-deficient IgG for diagnosis of chronic inflammatory diseases

Morishima, Naoki; Iwaisako, Maki; Kamada, Yoshihiro et al.

Clinica Chimica Acta, 2025, 566, 120052

Number of Access:2,110（2025-08-16 12:45 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/100205

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
ClinChimActa_566_120052	pdf	None	1.23 MB	52	2025.02.06

Creative Commons : Attribution - NonCommercial

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Generation and validation of antibody 42B1 recognizing galactose-deficient IgG for diagnosis of chronic inflammatory diseases
Creator	CreatorName Morishima, Naoki
	CreatorName Iwaisako, Maki
	NRID 1000030622609 1000030622609 ORCID 0000-0001-5485-902X 0000-0001-5485-902X researchmap permalink yk4478-jp yk4478-jp Scopus Author ID 7102943545 7102943545 CreatorName Kamada, Yoshihiro
	NRID 1000040397724 1000040397724 CreatorName Nakano, Miyako
	CreatorName Shiida, Masafumi
	CreatorName Ono, Tatsuya
	CreatorName Sonoda, Reika
	CreatorName Uemura, Risa
	CreatorName Sakon, Daisuke
	CreatorName Shimosaka, Munefumi
	NRID 1000000332669 1000000332669 researchmap permalink read0113178 read0113178 Scopus Author ID 8586166300 8586166300 CreatorName Takamatsu, Shinji
	NRID 1000080624593 1000080624593 ORCID 0000-0002-1350-0480 0000-0002-1350-0480 researchmap permalink jumpeko jumpeko Scopus Author ID 24767465900 24767465900 CreatorName Kondo, Jumpei
	NRID 1000020814601 1000020814601 researchmap permalink ty_gh ty_gh CreatorName Yoshihara, Takeo
	NRID 1000060546860 1000060546860 CreatorName Shinzaki, Shinichiro
	CreatorName Mita, Eiji
	NRID 1000070335355 1000070335355 researchmap permalink takeharatetsuo takeharatetsuo Scopus Author ID 7103332258 7103332258 CreatorName Takehara, Tetsuo
	CreatorName Kumada, Takashi
	CreatorName Yamada, Makoto
	NRID 1000020322183 1000020322183 ORCID 0000-0002-9430-2362 0000-0002-9430-2362 researchmap permalink read0068532 read0068532 Scopus Author ID 7005784183 7005784183 CreatorName Miyoshi, Eiji
Subject	Biomarker
	Chronic inflammatory diseases
	Galactose-deficient IgG
	Glycosylation
	IBD
	Next-generation glycan antibody
Description	Morishima N., Iwaisako M., Kamada Y., et al. Generation and validation of antibody 42B1 recognizing galactose-deficient IgG for diagnosis of chronic inflammatory diseases. Clinica Chimica Acta 566, 120052 (2025); https://doi.org/10.1016/j.cca.2024.120052.
Abstract	Galactose-deficient (agalactosyl) IgG is significantly increased in the serum of patients with rheumatoid arthritis, and autoantibodies against it are used in clinical tests. Subsequent studies also show increased agalactosyl IgG in many chronic inflammatory diseases. In this study, we generated antibody 42B1 recognizing agalactosyl IgG and developed a new method to evaluate chronic inflammatory diseases with it. Using an ELISA with antibody 42B1, we measured serum levels of agalactosyl IgG in 32 patients with inflammatory bowel disease (IBD), 60 patients with chronic liver disease, 60 patients with chronic pancreatitis, and 32 subjects undergoing health checkups who did not have IBD. Serum agalactosyl IgG levels were increased in all patients with chronic inflammations and partially correlated with clinical parameters. Among the subjects undergoing health checkups, some subjects showed a 15 % elevation of serum agalactosyl IgG levels, suggesting possible latent chronic inflammation. Future studies will examine the 42B1 antibody ELISA in various autoimmune diseases. Altogether, the 42B1 antibody for determination of serum agalactosyl IgG levels is a novel diagnostic tool for chronic inflammation.
Publisher	Elsevier B.V.
Source Title	Clinica Chimica Acta
Volume (Issue)	566
Page	120052
Date of Issued	2025-01-30
Language	English
Handle URL	https://hdl.handle.net/11094/100205
PISSN	00098981
eISSN	18733492
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.1016/j.cca.2024.120052
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCTERMS.bibliographicCitation	Clinica Chimica Acta. 2025, 566, p. 120052
DC.title	Generation and validation of antibody 42B1 recognizing galactose-deficient IgG for diagnosis of chronic inflammatory diseases
DC.creator	Morishima, Naoki
	Iwaisako, Maki
	Kamada, Yoshihiro
	Nakano, Miyako
	Shiida, Masafumi
	Ono, Tatsuya
	Sonoda, Reika
	Uemura, Risa
	Sakon, Daisuke
	Shimosaka, Munefumi
	Takamatsu, Shinji
	Kondo, Jumpei
	Yoshihara, Takeo
	Shinzaki, Shinichiro
	Mita, Eiji
	Takehara, Tetsuo
	Kumada, Takashi
	Yamada, Makoto
	Miyoshi, Eiji
DC.publisher	Elsevier B.V.
DC.language' scheme='DCTERMS.RFC1766	English
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2025-01-30
DC.identifier	https://doi.org/10.1016/j.cca.2024.120052
DC.subject	Biomarker
	Chronic inflammatory diseases
	Galactose-deficient IgG
	Glycosylation
	IBD
	Next-generation glycan antibody
DC.description	Morishima N., Iwaisako M., Kamada Y., et al. Generation and validation of antibody 42B1 recognizing galactose-deficient IgG for diagnosis of chronic inflammatory diseases. Clinica Chimica Acta 566, 120052 (2025); https://doi.org/10.1016/j.cca.2024.120052.
DCTERMS.abstract	Galactose-deficient (agalactosyl) IgG is significantly increased in the serum of patients with rheumatoid arthritis, and autoantibodies against it are used in clinical tests. Subsequent studies also show increased agalactosyl IgG in many chronic inflammatory diseases. In this study, we generated antibody 42B1 recognizing agalactosyl IgG and developed a new method to evaluate chronic inflammatory diseases with it. Using an ELISA with antibody 42B1, we measured serum levels of agalactosyl IgG in 32 patients with inflammatory bowel disease (IBD), 60 patients with chronic liver disease, 60 patients with chronic pancreatitis, and 32 subjects undergoing health checkups who did not have IBD. Serum agalactosyl IgG levels were increased in all patients with chronic inflammations and partially correlated with clinical parameters. Among the subjects undergoing health checkups, some subjects showed a 15 % elevation of serum agalactosyl IgG levels, suggesting possible latent chronic inflammation. Future studies will examine the 42B1 antibody ELISA in various autoimmune diseases. Altogether, the 42B1 antibody for determination of serum agalactosyl IgG levels is a novel diagnostic tool for chronic inflammation.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DC.format	100205
citation_title	Generation and validation of antibody 42B1 recognizing galactose-deficient IgG for diagnosis of chronic inflammatory diseases
citation_author	Morishima, Naoki
	Iwaisako, Maki
	Kamada, Yoshihiro
	Nakano, Miyako
	Shiida, Masafumi
	Ono, Tatsuya
	Sonoda, Reika
	Uemura, Risa
	Sakon, Daisuke
	Shimosaka, Munefumi
	Takamatsu, Shinji
	Kondo, Jumpei
	Yoshihara, Takeo
	Shinzaki, Shinichiro
	Mita, Eiji
	Takehara, Tetsuo
	Kumada, Takashi
	Yamada, Makoto
	Miyoshi, Eiji
citation_publisher	Elsevier B.V.
citation_language	English
citation_date	2025-01-30
citation_journal_title	Clinica Chimica Acta
citation_volume	566
citation_firstpage	120052
citation_doi	https://doi.org/10.1016/j.cca.2024.120052
citation_public_url	https://hdl.handle.net/11094/100205

Generation and validation of antibody 42B1 recognizing galactose-deficient IgG for diagnosis of chronic inflammatory diseases

Link to primary information

Item Information

Show details